ProPhase Labs, Inc. (PRPH) Stock Analysis
A live, multi-source view of ProPhase Labs, Inc. (PRPH): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About ProPhase Labs, Inc.
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides Nebula focuses on genomics testing technologies a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (DNA).
Sector: Healthcare · Industry: Diagnostics & Research · United States · 19 employees · prophaselabs.com
Key statistics · as of 2026-09-05
As of 2026-09-05, ProPhase Labs, Inc. (PRPH) had a market capitalization of $311,851 (forward 0.0) and a beta of 0.07; the shares traded in a 52-week range of $0.02 – $6.70 (-99.5% over the year).
- Market cap
- $311,851
- Enterprise value
- $9.4M
- Forward P/E
- 0.0
- EPS (trailing)
- $-0.99
- EPS (forward)
- $0.48
- Payout ratio
- 0.0%
- Ex-dividend date
- 2022-05-24
- 52-week range
- $0.02 – $6.70
- 52-week change
- -99.5%
- Beta
- 0.07
- Average volume
- 156,758
- Shares outstanding
- 15.6M
- Short % of float
- 0.71%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, ProPhase Labs, Inc. (PRPH) last closed at $0.02 (the last completed close before that scan).
Technicals at the scan: RSI 33 (neutral territory), price -33.3% versus its 20-day average, 20-day versus 50-day average spread -40.0%, MACD histogram 0.00.
Next scheduled company event: in 66 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for PRPH in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
PRPH has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls ProPhase Labs, Inc. (PRPH) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell PRPH.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.